SKYE
Income statement / Annual
Last year (2024), Skye Bioscience, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, Skye Bioscience, Inc.'s net income was -$26.57 M.
See Skye Bioscience, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$1.87 K
|
$1.46 K
|
$1.54 K
|
$8.04 K
|
$14.92 K
|
$9.95 K
|
| Gross Profit |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$1.87 K
|
-$1.46 K
|
-$1.54 K
|
-$8.04 K
|
-$14.92 K
|
-$9.95 K
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$18.70 M
|
$5.82 M
|
$6.01 M
|
$2.93 M
|
$1.94 M
|
$2.24 M
|
$329.97 K
|
$311.30 K
|
$939.04 K
|
$576.09 K
|
| General & Administrative Expenses |
$17.73 M
|
$7.85 M
|
$6.09 M
|
$4.92 M
|
$4.35 M
|
$4.40 M
|
$4.36 M
|
$3.55 M
|
$3.53 M
|
$3.74 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$17.73 M
|
$7.85 M
|
$6.09 M
|
$4.92 M
|
$4.35 M
|
$4.40 M
|
$4.36 M
|
$3.55 M
|
$3.53 M
|
$3.74 M
|
| Other Expenses |
-$6.23 M
|
$21.06 M
|
$6.21 M
|
$0.00
|
$0.00
|
$2.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$30.19 M
|
$34.74 M
|
$18.31 M
|
$7.85 M
|
$6.29 M
|
$6.63 M
|
$4.69 M
|
$3.86 M
|
$4.47 M
|
$4.32 M
|
| Cost And Expenses |
$30.19 M
|
$34.74 M
|
$18.31 M
|
$7.85 M
|
$6.29 M
|
$6.63 M
|
$4.69 M
|
$3.86 M
|
$4.47 M
|
$4.32 M
|
| Interest Income |
$3.26 M
|
$99.97 K
|
$19.01 K
|
$3.00
|
$29.00
|
$26.00
|
$84.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$967.60 K
|
$906.27 K
|
$663.77 K
|
$767.51 K
|
$706.39 K
|
$1.00 M
|
$94.76 K
|
$667.00
|
$0.00
|
$522.34 K
|
| Depreciation & Amortization |
$298.64 K
|
$124.25 K
|
$115.00 K
|
$34.13 K
|
$1.87 K
|
$1.46 K
|
$1.54 K
|
-$759.00 K
|
$14.92 K
|
$9.95 K
|
| EBITDA |
-$25.29 M |
-$36.62 M |
-$18.70 M |
-$7.72 M |
-$5.85 M |
$2.04 M |
-$4.69 M |
-$3.85 M |
$0.00 |
$0.00 |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$3.64 M
|
-$2.91 M
|
-$1.16 M
|
-$672.37 K
|
-$270.00 K
|
$7.69 M
|
-$14.50 M
|
$766.53 K
|
$1.29 M
|
-$522.34 K
|
| Income Before Tax |
-$26.56 M
|
-$37.64 M
|
-$19.47 M
|
-$8.52 M
|
-$6.56 M
|
$1.05 M
|
-$19.19 M
|
-$3.09 M
|
-$3.18 M
|
-$4.84 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$10.07 K
|
$3.60 K
|
$6.74 K
|
$2.10 K
|
$1.60 K
|
$1.60 K
|
$1.64 K
|
$1.60 K
|
$1.60 K
|
$1.72 K
|
| Net Income |
-$26.57 M
|
-$37.64 M
|
-$19.48 M
|
-$8.52 M
|
-$6.56 M
|
$1.05 M
|
-$19.19 M
|
-$3.09 M
|
-$3.18 M
|
-$4.84 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-0.73 |
-5.37 |
-8.77 |
-5 |
-7.11 |
1.98 |
-36.51 |
-25.62 |
-41.93 |
-71.45 |
| EPS Diluted |
-0.73 |
-5.37 |
-8.77 |
-5 |
-7.46 |
1.98 |
-36.51 |
-25.62 |
-39.9 |
-70.93 |
| Weighted Average Shares Out |
$36.49 M
|
$7.01 M
|
$2.22 M
|
$1.63 M
|
$922.99 K
|
$532.01 K
|
$525.78 K
|
$120.77 K
|
$75.79 K
|
$67.75 K
|
| Weighted Average Shares Out Diluted |
$36.49 M
|
$7.01 M
|
$2.22 M
|
$1.63 M
|
$925.68 K
|
$532.01 K
|
$525.78 K
|
$120.77 K
|
$79.65 K
|
$68.25 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
